PARTNERS

ISCT Asia 2026 Regional Meeting Corporate Partners & Supporters

Discover the organizations supporting the ISCT Asia 2026 Regional Meeting and advancing innovation across the cell and gene therapy ecosystem. Our partners and exhibitors represent a broad range of sectors, including Therapeutic Developers, Equipment and Device Providers, Manufacturing Platforms, Media & Reagent Suppliers, Not-for-Profit Organizations, Pharmaceutical Companies, CDMOs, and more.

Explore the list below to start planning the connections you’ll make in Singapore.

Platinum Sponsor

Miltenyi Biotec is a global leader in innovating technologies and services for patient-specific cell and gene therapies, turning scientific discoveries into practical treatments for personalized medicine. Having pioneered a groundbreaking method of cell separation, Miltenyi Biotec continues to set industry standards today. With over 35 years of expertise, it supports customers in biomedical discoveries, translating them into clinical applications to enable access to new therapies for patients. Miltenyi Biotec focuses on providing integrated, advanced solutions to address complex challenges in the treatment of cancers, autoimmune diseases, and inherited disorders. Through its Miltenyi Bioindustry division, it provides expert guidance to therapy developers, helping them efficiently and cost-effectively navigate the path from process development to commercialization. Miltenyi Biotec is headquartered in Bergisch Gladbach and has a global team of 4,700 employees across 24 countries.

Visit Website

Gold

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we're driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at Cytiva.com Cytiva is proud to be part of Danaher. Visit https://www.danaher.com/ to learn more about Danaher, a leading life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health.

Visit Website

Terumo Blood and Cell Technologies is a global medical technology company offering products, software, and services that enable the collection and preparation of blood and cells to treat challenging diseases. Within this organization, the Global Therapy Innovations delivers automated, closed-system solutions that support the entire vein-to-vein journey of cell and gene therapies ‚ from cell collection and expansion to fill and finish. Trusted by biotech companies, hospitals, and research institutions worldwide, we combine deep cell therapy insight with automation expertise to empower developers and manufacturers with GMP-compliant platforms that enhance consistency, reduce manual steps, and accelerate timelines from early research to commercialization. We believe in the power of blood and cells to do more for patients. This belief drives our innovation, fuels collaboration, and strengthens our commitment to expanding access to transformative therapies. We partner. We innovate. We accelerate.

Visit Website

Silver

Charles River provides essential products and services to support pharmaceutical and biotechnology companies, government agencies, and leading academic institutions worldwide in accelerating research and drug development. As a leader in scientific innovation, we are deeply committed to pioneering alternative methods that drive discovery while reducing reliance on traditional models. By embracing cutting-edge technologies and forward-thinking approaches, we enhance preclinical and clinical research. Our dedicated employees focus on delivering precisely what our clients need to improve, innovate, and expedite the discovery, early-stage development, and safe manufacture of new therapies for patients, because every moment matters. ‚ Biologics Testing Solutions With 50+ years of experience and over 40,000 tests run annually at the GMP biologics testing facilities, we provide comprehensive testing services for a wide range of modalities. ‚ Cell and Gene Therapy CDMO We have supported the development of 20 FDA-approved cell and gene therapies and have conducted more than 1,000 studies in this field over the past year.

Visit Website

Bronze

Agilent is a leader in life sciences, diagnostics, and applied chemical markets, delivering innovative technology solutions that provide trusted answers to researchers‚ most challenging scientific questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent‚ Newsroom.

Visit Website

Regenic is Indonesia's first cGMP-certified stem cell manufacturing facility, dedicated to advancing healthcare through innovative stem cell and secretome therapies. With state-of-the-art technology and a commitment to quality, safety, and ethics, we develop solutions for orthopedic conditions, chronic diseases, and more. Collaborating with hospitals and institutions, Regenic is driving the future of regenerative medicine, offering hope and new possibilities for improved health and quality of life. Headquartered at the Kalbe Business Innovation Centre (KBIC) in Jakarta, Regenic was founded in 2013 as a stem cell manufacturing and education center under PT Bifarma Adiluhung, a subsidiary of PT Kalbe Farma, Tbk. Regenic holds the distinction of being the first in Indonesia to achieve GMP certification from BPOM and an Operating License from the Ministry of Health (Kementerian Kesehatan), enabling us to manufacture clinical-grade stem cells and their metabolites products. Regenic aims to provide new hope for patients with unmet medical needs. In line with this vision, our mission is to consistently produce and deliver high-quality cell therapy products with integrity, prioritizing patient safety, product quality, and patient well-being. Our scope of business including Research and Development Centre for innovation cell therapy products, GMP manufacturing of allogenic stem cells and its derivatives, stem cell processing for autologous purposes, education center for stem cell.

Visit Website

In accordance with the commitment, TEIJIN group offers Contract Development and Manufacturing Organization (CDMO) services through the group companies TEIJIN REGENET and J-TEC. We specialize in Cell and Gene Therapies including tissue-engineered products, with the aim of supporting the process development and manufacturing of CGT products in Japan - taking innovative science from concept to patient treatment.

Visit Website

Supporter

Bluecord is a software company helping cell and gene therapy organizations digitize and connect their quality and manufacturing operations. Our cloud-based platform brings together Quality Assurance, Manufacturing, Inventory, and Quality Control into one integrated system built specifically for GMP environments. Developed in partnership with leading academic and clinical centers, Bluecord streamlines how teams manage documentation, deviations, batch records, and supplies. Every module is designed with regulatory readiness in mind, supporting HIPAA, 21 CFR Part 11, GAMP 5, and global data integrity standards. Today, Bluecord supports facilities across North America, Europe, and Asia-Pacific. Our mission is to make advanced therapy manufacturing simpler, safer, and faster so that life-changing treatments can reach patients sooner.

Visit Website

CytoNicheTM is revolutionizing the cell and gene therapy (CGT) industry with its scalable 3D FloTrixTM technology, offering comprehensive solutions for CGT manufacturing. Our product portfolio includes GMP-grade dissolvable microcarriers, serum-free media for mesenchymal stromal/stem cells, and a complete suite of GMP-compliant equipment and consumables. These solutions support every stage of cell production‚ from expansion and harvesting to processing and filling. Driven by a vision to ignite a new era in industrial cell development, we are empowering CGT advancements through intelligent, 3D cellular mass manufacturing technology. This innovation not only reduces production time and costs but also improves scalability, making it possible to produce billions of high-quality cells more efficiently than traditional methods. By reducing facility footprint, labor costs, and contamination risks, our technology is helping shape the future of sustainable biomanufacturing, bringing us closer to benefiting more patients around the world.

Visit Website

Promega is a global leader in innovative life science technologies, offering more than 4,000 products that accelerate research, drug discovery and development, and manufacturing. Promega provides a variety of solutions to meet the fast-growing demands in cell and gene therapy development. Our solutions enable sensitive, automation-friendly, quantitative analysis of AAV and Lenti genome titer, cell identity and purity, cell health, and potency‚ critical parameters for ensuring safety, consistency, and regulatory compliance in advanced therapy manufacturing. Our automated nucleic acids extraction and qPCR/ddPCR-based solutions help streamline analytical workflows for vector copy number and in vivo biodistribution studies. Promega partners closely with academic groups, industry leaders, and biomanufacturers to help standardize methods, improve analytical rigor, and accelerate the path from discovery to clinical impact. To learn more about how Promega supports cell and gene therapy development.

Visit Website

ISCT ASIA 2026 Singapore SUPPORTING ORGANIZATIONS

ACTRIS was established in April 2020 to meet the increasing clinical demand for cellular therapeutics to treat various life-threatening diseases. Our vision is to be the national and regional Centre of Excellence for facilitating discovery, process development, and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine, encompassing both investigational and clinical-use products for Singapore. Through its specialised infrastructure and skilled workforce, ACTRIS aims to promote and support the entire value chain of the cell therapy ecosystem by enabling translational research and development, manufacturing, clinical service provision, and commercialisation across the healthcare, academic and industrial sectors. In addition, ACTRIS will also provide value-added services such as workforce training, regulatory support, and the standardisation of ancillary materials and product testing pertaining to the delivery of cellular therapy to patients. ACTRIS is a programme of CRIS.

Visit Website